phosphorylcholine has been researched along with tamoxifen in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Degani, H; Neeman, M | 1 |
| Armes, SP; Craparo, EF; Giammona, G; Lewis, AL; Licciardi, M; Tang, Y | 1 |
| Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Seeber, S | 1 |
| Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L | 1 |
| Coelho, AC; Senra, L; Trinconi, CT; Uliana, SR; Yokoyama-Yasunaka, JK | 1 |
| Coelho, AC; Reimão, JQ; Trinconi, CT; Uliana, SR | 1 |
6 other study(ies) available for phosphorylcholine and tamoxifen
| Article | Year |
|---|---|
Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy.
Topics: Breast Neoplasms; Cell Line; Estradiol; Glucose; Glutamates; Glutamic Acid; Humans; Lactates; Lactic Acid; Magnetic Resonance Spectroscopy; Phosphates; Phosphorylcholine; Tamoxifen | 1989 |
in vitro biological evaluation of folate-functionalized block copolymer micelles for selective anti-cancer drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Caco-2 Cells; Drug Delivery Systems; Folic Acid; Humans; K562 Cells; Micelles; Paclitaxel; Phosphorylcholine; Polymethacrylic Acids; Tamoxifen | 2008 |
Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
Topics: Apoptosis; Aromatase; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Phosphorylcholine; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, G-Protein-Coupled; Receptors, Growth Factor; Signal Transduction; Tamoxifen | 2010 |
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
Leishmania is not prone to develop resistance to tamoxifen.
Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Leishmania; Leishmaniasis; Mice; Mice, Inbred BALB C; Phosphorylcholine; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Leishmania; Leishmaniasis, Cutaneous; Mice, Inbred BALB C; Parasite Load; Phosphorylcholine; Tamoxifen; Treatment Outcome | 2016 |